Table 1.
Baseline Study Variables
| Semaglutide n = 30 | Dulaglutide n = 30 | Metformin n = 20 | P | |
|---|---|---|---|---|
| Age (years) | 57 ± 10 | 55 ± 7.8 | 44 ± 12 | < 0.01 |
| Male (n) | 21 | 13 | 8 | |
| Ethnicity | ||||
| White | 17 | 18 | 9 | |
| Hispanic | 10 | 9 | 9 | |
| African American | 3 | 3 | 2 | |
| DM Hx (ys) | 7 ± 4 | 7 ± 4 | 2 ± 1 | < 0.01 |
| Weight (kg) | 105 ± 14 | 106 ± 21 | 94 ± 26 | ns |
| BMI (Kg/m2) | 34.3 ± 5 | 36.5 ± 6 | 33.5 ± 6 | ns |
| HbA1c (%) | 7.3 ± 1.2 | 8.2 ± 1.2 | 5.8 ± 0.6 | < 0.01 |
| c-peptide (ng/ml) | 3.8 ± 1.9 | 2.9 ± 1.8 | na | ns |
| SBP (mmHg) | 132 ± 13 | 127 ± 18 | 123 ± 15 | ns |
| DBP (mmHg) | 79.5 ± 8 | 76.8 ± 13 | 77.5 ± 9 | ns |
| HR (bpm) | 79 ± 10 | 83 ± 13 | 75 ± 13 | ns |
| LDL (mg/dl) | 99 ± 41 | 87 ± 33 | 116 ± 36 | ns |
| HDL (mg/dl) | 45 ± 16 | 43 ± 15 | 47 ± 11 | ns |
| TG (mg/dl) | 130 ± 65 | 125 ± 60 | 135 ± 50 | ns |
| EAT (mm) | 9.5 ± 2.6 | 9.2 ± 2.2 | 7.1 ± 2.1 | < 0.01 |
| Other diabetes meds | Metformin (30); SGLT2i (5); insulin (1) | Metformin (30); SGLT2i (6); insulin (3) | none | |
| Statins | 24 | 25 | 4 | |
| ACE-I or ARB | 18 | 19 | 4 |
Data are expressed as mean ± SD, or as actual number.
Abbreviations: ACE-I, ACE inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; DBP, diastolic blood pressure; DM hx, diabetes history; EAT, epicardial adipose tissue; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein cholesterol; HR, heart rate; LDL, low-density lipoprotein cholesterol; SBP, systolic blood pressure; SGLT2i, sodium glucose co-transporter 2 inhibitor; TG (triglycerides).